Skip to main content

Spero Therapeutics, Inc.

SPRO
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0001701108

No open-market purchases or sales by Spero Therapeutics, Inc. insiders were filed in the last 90 days; 59 institutions reported holding it in 13F filings for Q2 2026, worth $47.5M in total; no superinvestor holds it.

Q3 2024 vs. Q2 2024

How the institutions holding Spero Therapeutics, Inc. changed between Q2 2024 and Q3 2024.

All holders in Q3 2024All holders in Q2 2024

13F holders of SPRO: Q2 2024 compared with Q3 2024
MeasureQ2 2024Of which not filed for Q3 2024Q3 2024Change
Holders48146−1
Shares13.9M483.4K12.3M−1.05M (−7.8%)
Value$18.0M$628.4K$16.5M−$871.6K (−5.0%)

1 institution that held it in Q2 2024 haven't filed for Q3 2024 yet. Not filing isn't selling, so the changes leave them out.

New holders (6)

Institutions that held Spero Therapeutics, Inc. at the end of Q3 2024 but not at the end of Q2 2024.

Institutions new to SPRO in Q3 2024
InstitutionSharesValue% of portfolio
BlackRock, Inc.484,820$649.7K0.00%
PFG Investments, LLC13,979$18.7K0.00%
National Bank of Canada10,000$13.4K0.00%
CIBC Private Wealth Group, LLC2,880$3.86K0.00%
Simplex Trading, LLC921$1.00K0.00%
Northwestern Mutual Wealth Management Co50$670.00%

Sold out (7)

Institutions that held Spero Therapeutics, Inc. at the end of Q2 2024 and filed for Q3 2024 without it.

Institutions that sold out of SPRO in Q3 2024
InstitutionShares, Q2 2024Value, Q2 2024
Murchinson Ltd.873,910$1.14M
Two Sigma Securities, LLC67,728$88.0K
Texas Yale Capital Corp.10,000$13.0K
Royal Bank of Canada1,959$3.00K
Allworth Financial LP600$840
Rhumbline Advisers458$595
Qube Research & Technologies Ltd1$1

Not filed for Q3 2024 yet (1)

Institutions that held Spero Therapeutics, Inc. at the end of Q2 2024 and haven't filed a 13F for Q3 2024. Not filing isn't selling, so they aren't counted as sold out.

Institutions holding SPRO in Q2 2024 that haven't filed for Q3 2024
InstitutionShares, Q2 2024Value, Q2 2024
BlackRock Inc.483,402$628.4K